Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CIG
Havana, Cuba
- Ownership
- Private
- Employees
- ~1500
- Development stage
- Other
01
Overview
CIGB is a major Cuban biotech center developing vaccines, therapeutic proteins, monoclonal antibodies, and bioproducts for human and animal health, with a focus on infectious, cardiovascular, neurodegenerative, and neoplastic diseases. Exports products to over 40 countries and holds an extensive patent portfolio.
- Therapeutic areas
- CardiovascularImmunologyInfectious DiseasesNeurologyOtherOncology
- Modalities
- Recombinant proteinMonoclonal antibodyPeptideProteinVaccineCell therapyGene therapyFunctional foodAquaculture productGenetically improved plant
- Industry
- Pharma
02
Partnerships
BioCubaFarma global networkInternational codevelopment agreements
Beyond the preview
Go deeper on CIG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CIG.